NVCN

Eier musst haben

klar mit shorten machst du hier Kohle, die weiter zugenommen haben ;-)

und wird bestimmt noch mehr werden, mit dem Update

Largest Positive Changes an nr 1

+365%
www.wsj.com/mdc/public/page/2_3062-nasdaqshort-highlites.html

hier rein geht, der hat einen Schaden, lieber das Geld spenden

We have significant additional future capital needs and there are uncertainties as to our ability to raise additional funding.

lesen, anstatt nur auf Chart schauen ;-)))

The sale of Common Shares issued upon exercise of the Warrants or conversion of the Notes issued pursuant to the 2017 Financings could encourage short sales by third parties which could further depress the price of the Common Shares

das steht alles drin, troztallem gehen die ganzen Vollhonks hier rein, eigentlich unglaublich

und die eigene Meinung zählt ;-)

Volumina beachten +++

beachten, ist die ganze Zeit schon hoch, loooooll

du blinder ;-)

www.nasdaq.com/symbol/nvcn/historical

Ich kaufe ja erst heute ;-)

The Company must still regain compliance with the minimum bid price requirement under Listing Rule 5550(a)(2) before July 2, 2018. In the event the Company does not regain compliance by July 2, 2018, the Company may be eligible for additional time to regain compliance. To regain compliance, the closing bid price of the common shares of the Company (the "Common Shares") will need to be at least US$1.00 per share for a minimum of 10 consecutive business days. As previously disclosed, the Company will be seeking shareholder approval at its next Annual and Special General Meeting, scheduled for June 4, 2018, to carry out a share consolidation at an appropriate time to re-establish compliance with the US$1.00 minimum bid price requirement for listing on the Nasdaq Capital Market. Further information will be contained in the Company's Management Information Circular for its Annual and Special General Meeting. The Company is also listed on the Toronto Stock Exchange (the "TSX") and the Company's noncompliance with the Nasdaq minimum bid price requirement does not affect the Company's compliance status with the TSX.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace.  Its products include the Reducer, for the treatment of refractory angina, which is not currently available in the United States and has been available in Europe since 2015, and the Tiara, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada and Europe.  For more information, visit: www.neovasc.com.
This news release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws regarding the Company's plans and expectations concerning regaining compliance with the Bid Price Rule or receiving additional time to regain compliance, carrying out a share consolidation and remaining listed on the Nasdaq Capital Market. Words and phrases such as "continue", "until", "believe", "may", "intention", "could", "should", "expect" and "will", and similar words or expressions, are intended to identify these forward-looking statements. Forward-looking statements are based on estimates and assumptions made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company believes are appropriate in the circumstances. Many factors and assumptions could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the substantial doubt about the Company's ability to continue as a going concern; risks relating to the warrants (the "Warrants") and senior secured convertible notes (the "Notes") issued pursuant to the November 2017 underwritten public offering and concurrent private placement (together, the "2017 Financings"), resulting in significant dilution to the Company's shareholders; risks relating to the Company's need for significant additional future capital and the Company's ability to raise additional funding;  risks relating to cashless exercise and adjustment provisions in the Warrants and Notes issued pursuant to the 2017 Financings, which could make it more difficult and expensive for the Company to raise additional capital in the future and result in further dilution to investors; risks relating to the sale of a significant number of Common Shares of the Company; risks relating to the exercise of Warrants or conversion of Notes issued pursuant to the 2017 Financings, which may encourage short sales by third parties; risks relating to the possibility that the Company's Common Shares may be delisted from the Nasdaq Capital Market or the TSX, which could affect their market price and liquidity; risks relating to the Company's Common Share price being volatile; risks relating to the influence of significant shareholders of the Company over the Company's business operations and share price; risks relating to the Company's significant indebtedness, and its effect on the Company's financial condition; risks relating to claims by third parties alleging infringement of their intellectual property rights; risks relating to lawsuits that the Company is subject to, which could divert the Company's resources and result in the payment of significant damages and other remedies; the Company's ability to establish, maintain and defend intellectual property rights in the Company's products; risks relating to results from clinical trials of the Company's products, which may be unfavorable or perceived as unfavorable; the Company's history of losses and significant accumulated deficit; risks associated with product liability claims, insurance and recalls; risks relating to use of the Company's products in unapproved circumstances, which could expose the Company to liabilities; risks relating to competition in the medical device industry, including the risk that one or more of the Company's competitors may develop more effective or more affordable products; risks relating to the Company's ability to achieve or maintain expected levels of market acceptance for the Company's products, as well as the Company's ability to successfully build its in-house sales capabilities or secure third-party marketing or distribution partners; the Company's ability to convince public payors and hospitals to include the Company's products on their approved products lists; risks relating to new legislation, new regulatory requirements and the efforts of governmental and third-party payors to contain or reduce the costs of healthcare; risks relating to increased regulation, enforcement and inspections of participants in the medical device industry, including frequent government investigations into marketing and other business practices; risks associated with the extensive regulation of the Company's products and trials by governmental authorities, as well as the cost and time delays associated therewith; risks associated with post-market regulation of the Company's products; health and safety risks associated with the Company's products and industry; risks associated with the Company's manufacturing operations, including the regulation of the Company's manufacturing processes by governmental authorities and the availability of two critical components of the Reducer; risk of animal disease associated with the use of the Company's products; risks relating to the manufacturing capacity of third-party manufacturers for the Company's products, including risks of supply interruptions impacting the Company's ability to manufacture its own products; risks relating to the Company's dependence on limited products for substantially all of the Company's current revenues; risks relating to the Company's exposure to adverse movements in foreign currency exchange rates; risks relating to the possibility that the Company could lose its foreign private issuer status under U.S. federal securities laws; risks relating to breaches of anti-bribery laws by the Company's employees or agents; risks associated with future changes in financial accounting standards and new accounting pronouncements; risks relating to the Company's dependence upon key personnel to achieve its business objectives; the Company's ability to maintain strong relationships with physicians; risks relating to the sufficiency of the Company's management systems and resources in periods of significant growth; risks associated with consolidation in the health care industry, including the downward pressure on product pricing and the growing need to be selected by larger customers in order to make sales to their members or participants; risks relating to the Company's ability to successfully identify and complete corporate transactions on favorable terms or achieve anticipated synergies relating to any acquisitions or alliances; risks relating to the Company's ability to successfully enter into fundamental transactions as defined in the Series C warrants issued pursuant to the 2017 Financings; anti-takeover provisions in the Company's constating documents which could discourage a third party from making a takeover bid beneficial to the Company's shareholders; and risks relating to conflicts of interests among the Company's officers and directors as a result of their involvement with other issuers. These risk factors and others relating to the Company are discussed in greater detail in the "Risk Factors" section of the Company's Annual Report on Form 20-F (copies of which may be obtained at  www.sedar.com or www.sec.gov).  These factors should be considered carefully, and readers should not place undue reliance on the Company's forward-looking statements.  The Company has no intention and undertakes no obligation to update or revise any forward-looking statements or to provide information relating to further incremental exercises of Warrants or conversion of Notes beyond required periodic filings with securities regulators, whether as a result of new information, future events or otherwise, except as required by law.
View original content:www.prnewswire.com/news-releases/...-value-rule-300646557.html
SOURCE Neovasc Inc.

http://www.ariva.de/news/...-with-nasdaq-minimum-market-value-6969735

läuft hier, oder ??

www.barchart.com/story/stocks/quotes/NVCN/...-in-a-us-patient

?????????????????ß    10 Cent wäre mir lieber   nmM  

Die Frage ist, ob die über die 0,04$ kommt... anscheinend ist hier eine richtig dicke Mauer...
aber hat wer von euch Infos wie es überhaupt mit dem Listing am Nasdaq und mit der Bude überhaupt weitergeht?

Mit der Erlaubnis der Shareholder zum ReSplit können sie jetzt wohl eine Verlängerung beantragen, d.h. Nasdaq Delisting sollte verläufig nicht anstehen. Aber früher oder später sollten sie auf jeden Fall einen RS machen, weil mit 1.860.184.719 Outstanding Shares wird es schwierig auf die Dauer, da jemals etwas Bewegung nach oben reinzubringen. Meine Vermutung, paar gute News um den Kurs hochzutreiben, dann ein RS. Danach hoffentlich Dilution beendet, dann gehts auch wieder aufwärts.

@ Stresow: danke!
klingt ja mal nicht so verkehrt, hört sich nach nem Geduldsspiel an...dann warten wir halt, hab schon länger ne miniposi drin.

??????????????   https://www.ariva.de/news/...ck-in-amc-entertainment-holdings-7040335

da dürfte die 0,04   fallen   mit nur meiner Meinung und keine Empfehlung  

nochmal NEWS!!!
www.prnewswire.com/news-releases/...l-tvt-2018-300670471.html

Könnte das eine Trendwende werden? Sieht gar nicht schlecht aus im Moment  

nachdem jetzt 2 Meganews nacheinander kamen ist denk ich der Trend klar, allerdings weiß ich nicht wieviel der nützt bei der aktuellen Aktienlage der Bude und Finanziell?! weil Split muss ja irgendwann sein, sonst wird das Listing im NASDAQ ja nicht gewärleistet...
Vielleicht weiß einer hier im Board mehr...
meine Meinung